Investing into Ecrins Therapeutics promises a high return on investment:
- In vivo validated drug candidate ET-D5 developed for the treatment of several aggressive forms of cancer in human and veterinary oncology
- Strong current IP and commitment to boost the IP portfolio
- Exit scheduled at the end of the Clinical Proof of Concept
For investor relations enquiries please contact us.